Reliant Investment Partners LLC Acquires Shares of 342 Axon Enterprise, Inc $AXON

Reliant Investment Partners LLC bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the second quarter, Holdings Channel.com reports. The fund bought 342 shares of the biotechnology company’s stock, valued at approximately $283,000.

Other large investors have also recently made changes to their positions in the company. TCTC Holdings LLC increased its position in Axon Enterprise by 75.0% during the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after buying an additional 24 shares during the period. Bartlett & CO. Wealth Management LLC grew its position in shares of Axon Enterprise by 132.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 33 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of Axon Enterprise in the 1st quarter valued at $31,000. Catalyst Capital Advisors LLC purchased a new stake in Axon Enterprise in the 1st quarter valued at $32,000. Finally, Flaharty Asset Management LLC acquired a new stake in Axon Enterprise during the 1st quarter worth $33,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the sale, the president directly owned 238,379 shares in the company, valued at approximately $177,892,712.54. The trade was a 6.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $713.74, for a total transaction of $7,137,400.00. Following the completion of the transaction, the chief executive officer owned 3,033,982 shares of the company’s stock, valued at $2,165,474,312.68. This represents a 0.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,932 shares of company stock valued at $45,115,616 in the last quarter. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $749.00 on Tuesday. Axon Enterprise, Inc has a 52 week low of $422.38 and a 52 week high of $885.91. The company has a 50-day moving average price of $732.32 and a 200 day moving average price of $727.76. The company has a market cap of $58.80 billion, a P/E ratio of 184.94, a PEG ratio of 28.58 and a beta of 1.41. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same period in the prior year, the business posted $1.20 EPS. The company’s revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on AXON shares. JPMorgan Chase & Co. lifted their price objective on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research note on Thursday, July 17th. Northland Securities set a $800.00 price target on Axon Enterprise in a research report on Tuesday, August 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $870.00 price objective on shares of Axon Enterprise in a research report on Wednesday, September 24th. JMP Securities reiterated a “market outperform” rating and issued a $825.00 target price on shares of Axon Enterprise in a research note on Monday, September 29th. Finally, Zacks Research lowered Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 2nd. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.